Immunotherapy / PD-1 inhibitorFDA-approvedSecond-line
Opdivo
Generic name: nivolumab
How it works
Blocks a protein called PD-1 on immune cells, allowing them to recognize and attack cancer cells.
Cancer types
Lung Cancer— All patients
Melanoma— All patients
Efficacy
In clinical trials, nivolumab improved overall survival and progression-free survival in patients with non-small cell lung cancer.
Side effects
Mild
Most people tolerate this treatment well. Side effects are generally manageable and do not require stopping treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Nivolumab Improves Survival in Lung Cancer Patients | Lung Cancer | phase-3 | Event-free survival seemed to be prolonged with nivolumab (hazard ratio, 0.48; 95% confidence interval, 0.28-0.83) in patients with single or co-alterations in any of the KEAP1, STK11, CDKN2A and/or SMARCA4 driver genes. | Source → |
| Nivolumab plus ipilimumab treatment shows promise for Japanese patients with lung cancer | Lung Cancer | phase-3 | Median overall survival was 41.0 months versus 15.2 months, with a 5-year overall survival rate of 38% versus 16%. | Source → |
| Testing a Special Diet with Immunotherapy in Melanoma Patients | Melanoma | phase-2 | — | Source → |
| Testing a Combination of Bexmarilimab and Nivolumab in Cancer | Lung Cancer | phase-1 | — | Source → |
| Diabetes May Increase Side Effects of Cancer Treatment | Lung Cancer | observational | Nivolumab demonstrated similar antitumor activity in both groups, with no significant differences in median progression-free survival (PFS), overall survival (OS), or objective response rates. | Source → |
| Testing a Combination of Vaccines and Immunotherapy for Advanced Lung and Head and Neck Cancers | Lung Cancer | phase-1 | — | Source → |
| Testing a New Vaccine and Medicine for Liver Cancer and Metastases | Colorectal Cancer | phase-2 | — | Source → |
| Combination Therapy Tested in Colorectal Cancer | Colorectal Cancer | phase-1/2 | The median progression-free survival was 1.7 months in patients with PIK3CA wild-type tumors and 1.6 months in patients with PIK3CA-mutant tumors. | Source → |
| Testing a New Vaccine and Immunotherapy Combination for Colorectal and Pancreatic Cancer | Colorectal Cancer | phase-1 | — | Source → |
| Testing HLX18 vs. OPDIVO in Solid Tumors | Melanoma | phase-1 | — | Source → |
| Study Examines Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-2 | The confirmed PSA response rate was 21.6% in one group, and 20.5% in the other. | Source → |
| Testing Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Testing Immunotherapy for Localized Melanoma | Melanoma | phase-2 | — | Source → |
| Testing a New Combination Therapy for Advanced Colorectal Cancer | Colorectal Cancer | phase-1 | — | Source → |
| Rare Side Effect of Cancer Treatment Leads to Fatal Heart Attack | Melanoma | observational | — | Source → |
| Combining two cancer treatments may improve outcomes for some patients | Lung Cancer | phase-1/2 | Objective response rates were 18.2% for non-small-cell lung cancer, 18.5% for urothelial carcinoma, and 14.3% for hepatocellular carcinoma. | Source → |
| Immunotherapy Options for Colorectal Cancer | Colorectal Cancer | review | Pembrolizumab has a well-characterized long-term safety profile and superior progression-free and overall survival versus chemotherapy. | Source → |
| Combining Cancer Treatments Boosts Immune Response in Brain Metastases | Lung Cancer | lab-study | — | Source → |
| Evaluating Safety of Combination Therapy for Advanced Pancreatic Cancer | Pancreatic Cancer | phase-1 | — | Source → |
| Combining Radiotherapy and Immunotherapy for Lung Cancer | Lung Cancer | phase-2 | The objective response rate was 7% and 10% at 6 and 12 weeks, and reached 29% as the best response. | Source → |
| Testing Radiation Therapy with or without Nivolumab for Early or Recurring Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing Focused Ultrasound to Open Blood-Brain Barrier for Lung Cancer Brain Metastases | Lung Cancer | phase-3 | — | Source → |
| New Prognostic Tool for Lung Cancer Patients on Nivolumab | Lung Cancer | observational | Patients with a CHAM score ≥ 4 had median survival times of 6.7 and 18.7 months, respectively. | Source → |
| Comparing Blinatumomab Alone to Blinatumomab with Nivolumab in B-Cell Acute Lymphoblastic Leukemia | Leukemia | phase-2 | — | Source → |
| Fecal Microbiota Transplant and Anti-PD-1 Therapy for Metastatic Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Combining Immunotherapy and Radiation for Colorectal and Pancreatic Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Testing Combination Therapy for Richter's Transformation | Leukemia | phase-2 | — | Source → |
| Testing a New Treatment Combination for Advanced Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Comparing Nivolumab Administration at Home vs. in a Clinic | Colorectal Cancer | phase-2 | — | Source → |
| Study of Nivolumab and Relatlimab in Untreated Melanoma | Melanoma | phase-3 | — | Source → |
| Melanoma Treatment Trial Investigates New Combination Therapy | Melanoma | phase-2 | — | Source → |
| Treating Advanced Melanoma with Combination Therapies | Melanoma | phase-3 | — | Source → |
| New Test for Lung Cancer Patients May Predict Treatment Response | Lung Cancer | lab-study | The area under the curve for miR-3613-5p improved from 0.837 to 0.897, and the hazard ratio increased from 3.386 to 7.815. | Source → |
| Genetic Factors May Influence Antibody Response to Cancer Treatment | Melanoma | lab-study | — | Source → |
| Testing Nivolumab and Ramucirumab for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Comparing Treatments for Advanced Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing Nivolumab and Radiation Therapy for Brain Metastases from Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Taiwanese Study Examines Nivolumab and Chemotherapy for Lung Cancer | Lung Cancer | preclinical | — | Source → |
| Testing Nivolumab and Chemotherapy for Early Stage Lung Cancer in China | Lung Cancer | phase-2 | — | Source → |
| Testing Combination Therapy for Melanoma Brain Metastases | Melanoma | phase-2 | — | Source → |
| Testing a Combination Treatment for Metastatic Melanoma | Melanoma | phase-2 | — | Source → |
| Testing Nivolumab and Ipilimumab for Advanced Squamous Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing Nivolumab and Relatlimab for Melanoma Brain Metastases | Melanoma | phase-2 | — | Source → |
| Testing a Combination Treatment for Pancreatic and Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Study of Immunotherapy for High-Risk Melanoma | Melanoma | phase-2 | — | Source → |
| Testing New Treatments for Relapsed or Refractory Leukemia | Leukemia | phase-1 | — | Source → |
| Testing Nivolumab and Hydroxychloroquine for Advanced Melanoma | Melanoma | phase-1 | — | Source → |
| Stopping Combo Immunotherapy for Melanoma Brain Metastases May Be Safe | Melanoma | observational | 4-year OS exceeded 83% in patients discontinuing COMBO after CR, PR, or toxicity following CR, compared with 66.4% in those discontinuing due to toxicity after PR. | Source → |
| Pancreatic Cancer Vaccine Trial Evaluates Personalized Treatment | Pancreatic Cancer | phase-1 | — | Source → |
| Evaluating Adaptive Dosing of Immunotherapy for Metastatic Melanoma | Melanoma | phase-2 | — | Source → |
| Testing Nivolumab for Leptomeningeal Disease | Lung Cancer | phase-1 | — | Source → |
| Testing a New Treatment for Advanced Melanoma | Melanoma | phase-1 | — | Source → |
| Combination Therapy for Untreated Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| Testing Immunotherapy with Chemotherapy for Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Comparing Chemotherapy and Chemo-Immunotherapy for Non-Small Cell Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| Testing Olanzapine with Nivolumab for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing New Treatments for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Testing a New Approach to Treating Advanced Melanoma | Melanoma | preclinical | — | Source → |
| Testing Immunotherapy in Advanced Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Testing Nivolumab in Rare Solid Tumors | Breast Cancer | phase-2 | — | Source → |
| Testing Combination Therapy for Advanced Skin Cancers in Kidney Transplant Recipients | Melanoma | phase-1 | — | Source → |
| Melanoma Patient Responds to Repeated Treatment with Ipilimumab and Nivolumab | Melanoma | observational | — | Source → |
| New Combination Therapy Tested in Early-Stage Lung Cancer | Lung Cancer | phase-1/2 | The 36-month recurrence-free survival was 80%. | Source → |
| Survival Outcomes After Stopping Nivolumab Due to Side Effects in Lung Cancer | Lung Cancer | observational | The median overall survival was 35.73 months (95% CI: 30.06-41.40). | Source → |
| Testing New Cancer Treatment in Combination with Existing Medications | Lung Cancer | phase-1 | — | Source → |
| Rare Sleep Disorder Linked to Cancer Treatment | Melanoma | observational | — | Source → |
| Rare Blood Disorder in Lung Cancer Patient Treated with Nivolumab | Lung Cancer | observational | — | Source → |
| Nivolumab and Ipilimumab Combination Shows Promise in Some Cancer Patients | Colorectal Cancer | phase-2 | The disease control rates for breast cancer and other solid tumors were 33% and 32%, respectively. | Source → |
| Testing Defactinib, Avutometinib, and Nivolumab for Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Comparing Ways to Give Melanoma Medications | Melanoma | phase-2 | — | Source → |
| Testing IL2 and Immunotherapy in Advanced Melanoma Patients | Melanoma | phase-2 | — | Source → |
| Testing New Treatments for Advanced Melanoma | Melanoma | phase-2 | — | Source → |
| Testing Nivolumab with Standard Treatment for Colorectal Cancer with BRAF Mutation | Colorectal Cancer | phase-2 | — | Source → |
| Evaluating a New Combination Therapy for Advanced Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| COVID-19 Vaccination May Improve Lung Cancer Treatment | Lung Cancer | observational | Patients receiving ≥2 mRNA doses had significantly longer PFS2 than those receiving 0-1 dose (14.0 vs. 9.6 months; p = 0.04). | Source → |
| Evaluating Nivolumab and Ipilimumab in Combination with Chemotherapy for Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Immunotherapy May Offer Better Survival for Lung Cancer Patients with Poor Health | Lung Cancer | phase-3 | Median overall survival was significantly longer with nivolumab: 29-weeks (95% CI: 11.3-46.7) versus 8-weeks (95% CI: 3.5-12.5; p<0.001) | Source → |
| Melanoma Treatment Trial Investigates Combination of NeoVax and Immunotherapies | Melanoma | phase-1 | — | Source → |
| Preventing Melanoma Recurrence with Nivolumab | Melanoma | phase-3 | — | Source → |
| Evaluating Nivolumab and Docetaxel for Advanced Lung Cancer | Lung Cancer | preclinical | — | Source → |
| Testing Combination Therapy for Advanced Breast Cancer and Solid Tumors | Breast Cancer | phase-1 | — | Source → |
| Preventing Mucosal Melanoma Return After Surgery | Melanoma | phase-2 | — | Source → |
| Testing New Treatments for Advanced Melanoma That Has Progressed | Melanoma | phase-3 | — | Source → |
| Testing a New Combination Treatment for Advanced Lung Cancer | Lung Cancer | phase-2 | — | Source → |
| Low-dose nivolumab shows promise in treating lung cancer | Lung Cancer | phase-2 | The estimated 2-year event-free survival rate was 56.1% (95% confidence interval [CI]: 38.3%-73.9%), and the 2-year disease-free survival rate was 66.6% (95% CI: 56.4%-86.8%). | Source → |
| Testing a New Treatment for Advanced Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Testing Nivolumab to Prevent Leukemia Relapse | Leukemia | phase-2 | — | Source → |
| Testing Nivolumab and Ipilimumab with Radiation in Advanced Rectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Testing Immunotherapy After Surgery for High-Risk Melanoma | Melanoma | phase-3 | — | Source → |
| Trial Tests Cancer Drugs in HIV Patients | Breast Cancer | phase-1 | — | Source → |
| Testing Tocilizumab with Immunotherapy for Advanced Melanoma | Melanoma | phase-2 | — | Source → |
| Immunotherapy Shows Promise for Rare Ovarian and Cervical Cancers | Leukemia | phase-2 | The overall response rate was 9.38%, with two complete responses that are ongoing at >3 years and one partial response. | Source → |
| Nivolumab's Safety and Effectiveness in Chinese Lung Cancer Patients | Lung Cancer | observational | The median overall survival was 21.2 months. | Source → |
| B cells and genetic changes may predict response to cancer treatment | Ovarian Cancer | phase-2 | More than two passenger fusion genes were detected in six of the seven responders, whereas eight of the ten non-responders lacked fusion genes. | Source → |
| GRIm Score Predicts Response to Melanoma Treatment | Melanoma | observational | Patients with a low GRIm Score had significantly longer median progression-free survival (21.4 vs. 6.3 months, p = 0.003) and overall survival (26.5 vs. 7.2 months, p < 0.001). | Source → |
| Combining Immunotherapy for Advanced Anal Cancer | Colorectal Cancer | phase-2 | The median progression-free survival was 2.9 months for nivolumab and 3.7 months for nivolumab plus ipilimumab. | Source → |
| Fatal Lung Disease after Lung Cancer Treatment | Lung Cancer | observational | — | Source → |
| New Biomarker Predicts Outcomes for Lung Cancer Patients on Nivolumab | Lung Cancer | observational | Patients with GLR <70.76 achieved significantly longer OS (median 24.1 vs 9.6 months; p < 0.001) and PFS (9.7 vs 5.8 months; p < 0.001) compared with those with GLR ≥70.76. | Source → |
| Immunotherapy Response Predicted by Low Tumor Mutation Burden and PD-L1 Expression | Melanoma | observational | — | Source → |
| Long-term remission in lung cancer patient treated with nivolumab | Lung Cancer | observational | The patient remained in continuous remission with a progression-free survival exceeding 82 months and an overall survival exceeding 84 months. | Source → |
| Combining TM5614 and Nivolumab to Treat Advanced Melanoma | Melanoma | phase-3 | — | Source → |
| Rare Side Effect of Cancer Treatment in Older Patient | Melanoma | observational | — | Source → |
| Combination Therapy for Metastatic Melanoma Shows Promise in Real-World Study | Melanoma | observational | The response rate was 54% (39/72) and, after 13.6 months of median follow-up, a longer median progression-free survival [17.03 months (95% CI 4.8-18.6)]. | Source → |
| Blood Transfusions May Affect Lung Cancer Treatment Outcomes | Lung Cancer | observational | Median progression-free survival was 5.93 months, and median overall survival was 8.23 months. | Source → |
| Combination Cancer Therapy Linked to Kidney and Pancreas Damage | Lung Cancer | observational | — | Source → |
| Cost-Effectiveness of Lung Cancer Treatment Questioned | Lung Cancer | phase-3 | Nivolumab plus bevacizumab and chemotherapy yielded an additional 0.90 QALYs with the marginal cost of $231,948.33. | Source → |
| New Study Explores Using Nivolumab to Treat Malignant Ascites | Pancreatic Cancer | phase-2 | Seven patients (77.8%) showed a clinical response. | Source → |
| Melanoma Study Examines Vaccine Combination with Immunotherapy | Melanoma | phase-2 | Objective response rates were 59.7% and 59.2% in the two treatment arms. | Source → |
| Combining Nivolumab with Chemotherapy for Advanced Ovarian Cancer | Ovarian Cancer | phase-2 | Fifteen of the 20 evaluable patients had complete gross resection at ICS, and 7 of 20 achieved an optimal pathologic chemotherapy response score of 3. | Source → |
| Immune therapy may trigger severe colitis in some patients | Melanoma | observational | — | Source → |
| Combination Treatment Shows Promise for Rare Gynecological Cancers | Ovarian Cancer | phase-2 | The overall objective response rate was 54% (95% CI, 35-71), with 3 (12%) complete responses and 12 (42%) partial responses. | Source → |
| Study Examines Combination Therapy for Advanced Liver Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Cost-effectiveness of dual immunotherapy for lung cancer | Lung Cancer | phase-3 | Nivolumab plus ipilimumab provided an incremental gain of 1.11 and 0.96 QALYs over chemotherapy in the USA and China, respectively. | Source → |
| Comparing Two Ways to Give Cancer Treatment | Melanoma | phase-2 | — | Source → |
| Long-term Survival and Response to Immunotherapy in Melanoma Patients | Melanoma | phase-2 | At 4 years from the start of treatment, 80% of patients remained event-free, including 95% of patients who achieved a major pathologic response. | Source → |
| Combining RP1 and Nivolumab May Help Some Melanoma Patients | Melanoma | phase-2 | The confirmed objective response rate was 32.9% (95% CI, 25.2% to 41.3%; 15.0% complete response). | Source → |
| Rare Side Effect of Cancer Treatment: Tongue Discoloration | Ovarian Cancer | observational | — | Source → |
| TIL Therapy for Melanoma Patients May Benefit from IFNα Support | Melanoma | phase-2 | Disease control was obtained in 11.1% of the patients treated without IFNα and in 41.7% of the patients treated with IFNα. | Source → |
| Combination Therapy Improves Survival in Advanced Melanoma Patients | Melanoma | preclinical | The 4-year progression-free survival rate was 30.6% for nivolumab plus relatlimab versus 23.6% for nivolumab alone. | Source → |
| Combination Therapy Shows Promise for Metastatic Uveal Melanoma | Melanoma | observational | — | Source → |
| Nivolumab Fails to Improve Remission in Acute Myeloid Leukemia | Leukemia | phase-2 | The median progression-free survival was 13.2 months in the Nivo arm and 10.9 months in the Obs arm. | Source → |
| Color Vision Loss in Melanoma Patient Treated with Nivolumab-Relatlimab | Melanoma | observational | — | Source → |
| Nivolumab Treatment in Melanoma Patients: Immune and Nutritional Status Linked to Survival | Melanoma | observational | Patients with high HALP scores had significantly longer progression-free survival (PFS: median 5.8 vs 3.1 months) and overall survival (OS: median 54.9 vs 14.4 months) compared to those with low HALP scores. | Source → |
| Combining Telaglenastat and Nivolumab in Cancer Treatment | Melanoma | phase-1/2 | The overall response rate was 8.4% in the response-assessable analysis set. | Source → |
| Rare Side Effects of Cancer Treatment | Melanoma | observational | — | Source → |
| Nivolumab Effectiveness in Non-Small Cell Lung Cancer | Lung Cancer | observational | The 36-month OS rate was 19.7% (95% confidence interval [CI] 17.5-22.0); the 12-month investigator-assessed best ORR in the overall population was 20.4%. | Source → |
| Rare Side Effect of Cancer Treatment | Melanoma | observational | — | Source → |
| Brazilian Study Examines Cost of New Melanoma Treatments | Melanoma | observational | — | Source → |
| Inflammatory Markers and Metastases Predict Nivolumab Response in Lung Cancer | Lung Cancer | observational | The median overall survival was 21.2 months (95% CI: 17.4-25.0). | Source → |
| Researchers Test New Cancer Treatment in Rare Ovarian Cancers | Ovarian Cancer | phase-2 | The overall response rate was 25% in granulosa cell tumors, with 50% of patients experiencing clinical benefit. | Source → |
| Combination Therapy for Lung Cancer: A Meta-Analysis | Lung Cancer | meta-analysis | Non-small cell lung cancer patients who received combination therapy had better progression-free survival (HR = 0.82, 95% CI 0.71; 0.93, P < 0.01). | Source → |
| Relatlimab/Nivolumab Combination Therapy for Advanced Melanoma | Melanoma | review | — | Source → |
| Combining Entinostat and Nivolumab in Pancreatic Cancer | Pancreatic Cancer | phase-2 | The objective response rate was 11% (95% CI, 2.4%-29.2%) with a median response duration of 10.2 months. | Source → |
| Long-term Outcomes for Melanoma Patients Treated with Nivolumab and Ipilimumab | Melanoma | phase-3 | OS was longer with NIVO + IPI versus NIVO monotherapy (hazard ratio, 0.78 [95% CI, 0.67 to 0.91]), with 6-year OS rates of 52% versus 41%, respectively. | Source → |
| Melanoma patients' quality of life during immunotherapy treatment | Melanoma | observational | — | Source → |
| Melanoma Patients' Long-Term Survival Rates After Treatment | Melanoma | phase-3 | Estimated cure rates were 48.3% with nivolumab, 38.2% with ipilimumab, and 29.2% with placebo. | Source → |
| Long-term Outcomes with Nivolumab and Ipilimumab in Advanced Melanoma | Melanoma | phase-3 | Median overall survival was 71.9 months with nivolumab plus ipilimumab, 36.9 months with nivolumab, and 19.9 months with ipilimumab. | Source → |
| Study Compares Cancer Treatments for Rare Melanoma in Japanese Patients | Melanoma | observational | Objective response rates did not differ significantly between the NIVO+IPI and PD-1 groups (40.0% vs 27.7%). | Source → |
| Researchers Study Effectiveness of Cancer Treatment with Adaptive Dosing | Melanoma | phase-2 | The overall response rate was 47% (95% CI, 35%-59%) with a median follow-up of 34 months among survivors. | Source → |
| Melanoma Treatment Comparison Study Finds Similar Efficacy | Melanoma | phase-3 | Nivolumab plus relatlimab demonstrated similar progression-free survival (hazard ratio, 1.08 [95% CI, 0.88 to 1.33]) and overall survival (HR, 0.94 [95% CI, 0.75 to 1.19]) to nivolumab plus ipilimumab. | Source → |
| Combination Therapy Shows Promise in Lung Cancer Treatment | Lung Cancer | phase-2 | The estimated mean 6-month progression-free survival rate was 68.9% (high-MET group) and 50.9% (low-MET group). | Source → |
| Woman's Rare Brain Inflammation Linked to Cancer Treatment | Lung Cancer | observational | — | Source → |
| Nivolumab Monotherapy and Salvage Immunotherapy in Advanced Kidney Cancer | Melanoma | phase-2 | The 36-month mean time on protocol therapy was 11.5 months, and the 36-month mean TFS for the whole population was 9.4 months. | Source → |
| Nivolumab Shows Promise in Treating Rare Cancer | Lung Cancer | observational | The response rate was 8%, disease control rate was 37%, median progression-free survival was 5.7 months, and median overall survival was 11.1 months. | Source → |
| New Insights into Cancer Treatment for Children | Melanoma | phase-2 | — | Source → |
| Nivolumab treatment helps patient with advanced melanoma and liver failure | Melanoma | observational | — | Source → |
| Combining Vaccine and Immunotherapy in Early Prostate Cancer | Prostate Cancer | phase-2 | 21% of patients had a PSA decline >50%. | Source → |
| Nivolumab Not Cost-Effective for Relapsed Mesothelioma in China | Lung Cancer | phase-3 | Patients receiving nivolumab gained 0.65 quality-adjusted life-years (QALYs) compared to 0.43 QALYs for those receiving a placebo. | Source → |
| Combining Nivolumab and Chemotherapy in Lung Cancer Treatment | Lung Cancer | phase-3 | Median OS was 18.8 months with nivolumab plus chemotherapy versus 15.6 months with chemotherapy in patients with nonsquamous NSCLC. | Source → |
| Immunotherapy Shows Promise for Advanced Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| New Lung Cancer Treatment Combination Shows Mixed Results | Lung Cancer | phase-3 | The clinical benefit rate was 75.5% for sitra + nivo and 64.5% for docetaxel. | Source → |
| Combination Therapy Shows Promise for Advanced Melanoma | Melanoma | observational | — | Source → |
| Immune Checkpoint Inhibitors May Reduce Costs of Cancer Treatment | Lung Cancer | phase-3 | — | Source → |
| Combining Cancer Treatments May Help Some Patients with Advanced Melanoma | Melanoma | phase-2 | The combination of nivolumab and ipilimumab resulted in a statistically significant improvement in progression-free survival over ipilimumab (hazard ratio = 0.63). | Source → |
| Japanese Study Finds Safety of Nivolumab and Ipilimumab Combination Therapy for Melanoma | Melanoma | observational | — | Source → |
| Combining Immunotherapy Treatments Shows Promise in Pancreatic Cancer | Pancreatic Cancer | phase-2 | Treatment with GVAX+nivolumab+urelumab meets the primary endpoint by significantly increasing intratumoral CD8+ CD137+ cells (p = 0.003) compared to GVAX+Nivolumab. | Source → |
| Relatlimab-Nivolumab Combination for Metastatic Melanoma | Melanoma | review | — | Source → |
| Combining two drugs may help some patients with rare cancer complication | Leukemia | phase-2 | The overall response rate was 42%. | Source → |
| Combination Immunotherapy for Melanoma Brain Metastases | Melanoma | observational | Median overall survival was 5.45 months, with 21% of patients alive after 3 years. | Source → |
| Nivolumab Plus Relatlimab Shows Promise in Treating Advanced Melanoma | Melanoma | phase-2 | — | Source → |
| Melanoma Treatment Costs and Use Vary by Therapy Type | Melanoma | observational | — | Source → |
| Combining Nivolumab and Relatlimab to Treat Melanoma | Melanoma | phase-3 | Nivolumab and relatlimab produced more than a 2-fold median increase in progression-free survival (PFS) compared to nivolumab monotherapy. | Source → |
| Predicting Nivolumab Efficacy in Lung Cancer Patients | Lung Cancer | observational | The objective response and disease control rates at 25 weeks were 18.5 and 41.2%, respectively. | Source → |
| Combination Therapy Shows Promise in Treating Advanced Melanoma | Melanoma | phase-3 | The estimated 5-year RFS and OS rates for the neoadjuvant arm were 70% and 90% versus 60% and 70% for the adjuvant arm. | Source → |
| Sema4D silencing may improve melanoma treatment with nivolumab | Melanoma | lab-study | — | Source → |
| IMDC Risk Score Predicts Nivolumab Effectiveness in Renal Cancer and Melanoma | Melanoma | observational | — | Source → |
| Nivolumab Tested in Rare Cancer | Lung Cancer | phase-2 | — | Source → |
| Combining Immunotherapy for Melanoma Treatment | Melanoma | phase-2 | — | Source → |
| Nivolumab Levels Linked to Melanoma Treatment Outcomes | Melanoma | observational | — | Source → |
| Combination Immunotherapy Shows Promise in Treating Melanoma | Melanoma | phase-2 | The pathologic complete response rate was 57%. | Source → |
| New Treatment Option for Advanced Melanoma Patients | Melanoma | phase-1/2 | Nivolumab/relatlimab demonstrated a median progression-free survival (PFS) of 10.1 months. | Source → |
| Melanoma Treatment Comparison Study | Melanoma | phase-3 | The 2-year overall survival for those starting on arm A was 71.8% (95% CI, 62.5 to 79.1), and arm B 51.5% (95% CI, 41.7 to 60.4). | Source → |
| Combination Therapy Does Not Improve Survival in Melanoma Patients | Melanoma | phase-3 | 24-month RFS rates were 64.6% (combination) and 63.2% (nivolumab). | Source → |
| Combination Therapy Fails to Improve Lung Cancer Treatment | Lung Cancer | phase-2 | The objective response rate was 3.2%. | Source → |
| Side Effects of Cancer Treatment: A Rare Case of Colitis | Melanoma | observational | — | Source → |
| Rare Skin Reaction in Child with Cancer Treated with Nivolumab | Melanoma | observational | — | Source → |
| Real-world safety of nivolumab in melanoma patients | Melanoma | observational | — | Source → |
| Nivolumab Retreatment in Lung Cancer Patients | Lung Cancer | phase-2 | Nivolumab retreatment demonstrated an overall response rate of 8.5% and median progression-free survival of 2.6 months. | Source → |
| Long-term benefit of nivolumab plus low-dose ipilimumab in colorectal cancer | Colorectal Cancer | phase-2 | The investigator-assessed objective response rate increased from 55% to 65% at 50.9 months. | Source → |
| Rare Skin Cancer Linked to Melanoma Treatment | Melanoma | observational | — | Source → |
| Combining Immunotherapy and Radiation for Pancreatic Cancer | Pancreatic Cancer | phase-2 | The clinical benefit rate was 17.1% for patients receiving nivolumab and radiation, and 37.2% for patients receiving nivolumab and ipilimumab with radiation. | Source → |
| New Study Compares Melanoma Treatment with Two Immunotherapy Drugs | Melanoma | phase-3 | — | Source → |
| Nivolumab Monotherapy for Advanced Lung Cancer in Asian Patients | Lung Cancer | phase-3 | Median overall survival was 14.7 months, and median progression-free survival was 3.6 months. | Source → |
| Neutrophils May Help Predict Melanoma Treatment Outcomes | Melanoma | lab-study | Patients with lower PD-L1 PMN frequencies displayed better progression-free survival (PFS) and overall survival (OS) compared to patients with high PD-L1 PMN frequencies. | Source → |
| Nivolumab treatment in patients with kidney failure | Melanoma | observational | — | Source → |
| Long-term Outcomes of Melanoma Treatment with Nivolumab and Ipilimumab | Melanoma | phase-3 | Median overall survival was 72.1, 36.9, and 19.9 months in the combination, nivolumab, and ipilimumab groups, respectively. | Source → |
| Rare Side Effects of Cancer Treatment Cause Oral Ulcers and Adrenal Insufficiency | Lung Cancer | observational | — | Source → |
| Nivolumab Dose Escalation Triggers Rare Side Effect in Lung Cancer Patient | Lung Cancer | observational | — | Source → |
| Ipilimumab and Nivolumab Show Promise in Rare Aggressive Breast Cancer | Breast Cancer | phase-2 | The overall response rate was 18%. | Source → |
| Reusing Cancer Treatment May Not Work as Well Second Time Around | Melanoma | observational | The best overall response rate was 74% after the first course of ipilimumab/nivolumab, but only 23% after reinduction. | Source → |
| Rucaparib and Nivolumab Tested as Maintenance Treatment for Ovarian Cancer | Ovarian Cancer | phase-3 | — | Source → |
| Gastric Cancer Study Finds Tumor Mutation Burden and Indel Rate Linked to Treatment Outcomes | Leukemia | phase-2 | Patients with TMB ≥ 18.03/Mb and an indel rate of > 40% had a hazard ratio of 0.07 for progression-free survival and 0.09 for overall survival. | Source → |
| New Treatment Option for Advanced Lung Cancer | Lung Cancer | phase-3 | Overall survival was improved for patients who received nivolumab and ipilimumab, with a median OS of 18.1 months compared with 14.1 months for patients who received chemotherapy. | Source → |
| Nivolumab Safety in Stage III/IV Melanoma Patients | Melanoma | phase-3 | — | Source → |
| Rare Mediastinal Melanoma Shrinks with Immunotherapy | Melanoma | phase-2 | nivolumab monotherapy caused remarkable tumor shrinkage | Source → |
| New Tool Helps Doctors Decide Next Steps for Lung Cancer Patients | Lung Cancer | lab-study | — | Source → |
| Rare Skin Reaction Linked to Cancer Treatment | Melanoma | observational | — | Source → |
| Nivolumab treatment for HIV-infected lung cancer patients | Lung Cancer | phase-2 | The disease control rate was 62.5% for 15 evaluable patients at 8 weeks. | Source → |
| Weight Loss Linked to Poor Prognosis in Lung Cancer Patients | Lung Cancer | observational | Loss of body weight of >2% at week 6 was an independent predictor for poor OS (hazard ratio 2.39, 95% confidence interval 1.51-3.79, P < 0.001) | Source → |
| Rare Esophageal Cancer Treated with Nivolumab | Melanoma | observational | — | Source → |
| Rare Lymphoma Linked to Cancer Treatment | Lung Cancer | observational | — | Source → |
| Lung Cancer Study Finds New Way to Predict Treatment Success | Lung Cancer | observational | Median progression-free survival for subjects with NLR <3 before treatment was 18.5 weeks, while in subjects with NLR ≥3 was 14 weeks. | Source → |
| Nivolumab Fails to Improve Survival in Relapsed Small-Cell Lung Cancer | Lung Cancer | phase-3 | Median progression-free survival was 1.4 versus 3.8 months (HR, 1.41; 95% CI, 1.18-1.69). | Source → |
| Rare Side Effects of Cancer Treatment | Melanoma | observational | — | Source → |
| Cost-effectiveness of nivolumab in treating small cell lung cancer | Lung Cancer | phase-3 | Mean overall survival was 21.69 months with nivolumab and 5.80 months with IV or oral topotecan. | Source → |
| Large Spleen May Predict Poor Outcomes in Pancreatic Cancer Treatment | Pancreatic Cancer | observational | Among 31 evaluable patients, the response and disease control rates were 7% and 36%, respectively. | Source → |
| Gene Expression May Predict Response to Cancer Treatment | Lung Cancer | lab-study | — | Source → |
| Testing for Cancer Gene May Improve Effectiveness of Lung Cancer Treatment in China | Lung Cancer | phase-3 | The PD-L1 test-based strategy yielded an additional 0.27 QALYs compared to the docetaxel strategy without a PD-L1 test. | Source → |
| Combining Cancer Drugs with Anti-Inflammatory Medications in Melanoma Patients | Melanoma | preclinical | Seven of seven evaluable patients achieved objective response, including four complete responses and three partial responses, in the certolizumab cohort. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.